Bozeman, MT (PressExposure) July 01, 2008 -- With contaminations of foreign made food and drug products coming to light constantly, consumers have become increasingly and rightfully fearful about the origin of their consumable goods. For example, the contaminations of the blood thinner heparin alone killed over 100 people. The heparin was contaminated in the production process because of lax enforcement of manufacturing rules and regulations. In response to this, recent draft legislation proposed by the U.S. Food and Drug Administration (FDA) seeks to increase the number of foreign facility inspections and establish permanent operations in China.
In response to this growing threat to the American people, Aim & Act, Incorporated, an upstart firm is seeking to work with Chinese manufacturers to provide safer products to the United States. Aim & Act provides scientific marketing and consulting services internationally to pharmaceutical, natural products and medical device companies. With significant competency in Quality Assurance, Good Manufacturing Practices, Good Laboratory Practices as well as Process Design and Validation, Aim & Act is one of the only companies willing or able to take on this problem.
By concentrating much of its effort on Chinese companies and production facilities, Aim & Act hopes to assist foreign companies in applying the same standards of excellence in manufacturing found in the United States. Aim & Act hopes to stop other unnecessary contaminations before they happen. In less than one week, most manufacturing processes can complete a quality assurance audit. This detailed examination of each step in a manufacturing process identifies any problem areas and reduces the possibility of contaminations to virtually none.
"Inconsistencies and contaminations in manufacturing are easily avoided with a relatively minor investment of time and money" said Andrew Buirge, President of Consulting for Aim & Act, "but these kinds of contaminations are continuing to happen far too frequently and innocent people are dying because of it."
Through a unique business model, Aim & Act bridges the traditional gap between marketing and science for foreign and domestic companies, thereby facilitating greater product uptake and return on investment for client companies.